The FDA is undergoing significant senior leadership turnover, intensifying industry and market uncertainty. Jacqueline Corrigan-Curay, acting director of the Center for Drug Evaluation and Research, announced retirement effective July. This follows earlier removals including Nicole Verdun, director of the cell and gene therapy office, and others associated with critical therapeutic areas. The new leadership under Commissioner Marty Makary has introduced policy changes affecting approval standards and agency operations. The transition has sparked concerns about continuity and regulatory stability in high-impact therapy sectors like gene editing and cell therapy.